Document:

EX-10.69

 Exhibit 10.69 

HORIZON PHARMA, INC. 

FIRST AMENDMENT TO 

EXECUTIVE EMPLOYMENT AGREEMENT 

This First Amendment to Executive Employment Agreement (this “Amendment”), amending that certain Executive
Employment Agreement dated February 16, 2017 (the “Employment Agreement”), by and among Horizon Pharma, Inc., a Delaware corporation, and its wholly owned subsidiary, Horizon Pharma USA, Inc., a Delaware corporation
(hereinafter referred to together as the “Company”), and Michael DesJardin (the “Executive”), is entered into as of May 4, 2017 by and among the Company and the Executive. Capitalized terms used
herein which are not defined herein shall have the definition ascribed to them in the Employment Agreement. 
 RECITALS 

WHEREAS, the Company and the Executive have previously entered into the Employment Agreement; 

WHEREAS, Section 9 of the Employment Agreement provides that the Employment Agreement may be amended with the
written agreement of the Company and the Executive; and 
 WHEREAS, the Company and the Executive desire to amend the
Employment Agreement as set forth herein. 
 AGREEMENT 

NOW, THEREFORE, in consideration of the foregoing and the promises and covenants contained herein and in
the Employment Agreement, and for other good and valuable consideration, the receipt of which is hereby acknowledged, the parties hereto agree as follows: 

1.    Section 4.4.3 of the Employment Agreement. Section 4.4.3 of the Employment Agreement is hereby
amended and restated in its entirety to read as follows: 
 “4.4.3 Without Cause or For Good Reason.  

(i)    Not in Connection With a Change in Control. If the Company terminates the
Executive’s employment without Cause or the Executive terminates his employment for Good Reason, and Section 4.4.3(ii) below does not apply, the Company shall pay the Accrued Amounts subject to standard deductions and withholdings, to be
paid as a lump sum no later than thirty (30) days after the date of termination. In addition, subject to the limitations stated in this Agreement and upon the Executive’s furnishing to the Company an executed waiver and release of claims
(the form of which is attached hereto as Exhibit A) (the “Release”) within the applicable time period set forth therein, but in no event later than forty-five days following termination of employment and permitting such
Release to become effective in accordance with its terms (the “Release  

  
 1. 

 
Effective Date”), and subject to Executive entering into no later than the Release Effective Date a non-competition agreement to be
effective during the Severance Period (as defined below), substantially similar to Section 2.3, and continuing to abide by its terms during the Severance Period, the Executive shall be entitled to: 

(a)     the equivalent of the Executive’s Base Salary in effect at the time of termination
will continue to be paid for a period of twelve (12) months following the date of termination (hereinafter referred to as the “Non Change in Control Severance Period”), less standard deductions and withholdings, to
be paid during the Non Change in Control Severance Period according to the Company’s regular payroll practices, subject to any delay in payment required by Section 4.6 in connection with the Release Effective Date; and 

(b)     in the event the Executive timely elects continued coverage under COBRA, the Company will
continue to pay the same portion of Executive’s COBRA health insurance premium as the percentage of health insurance premiums that it paid during the Executive’s employment, including any amounts that Company paid for benefits to the
qualifying family members of the Executive, following the date of termination up until the earlier of either (i) the last day of the Non Change in Control Severance Period or, (ii) the date on which the Executive begins full-time
employment with another company or business entity which offers comparable health insurance coverage to the Executive (such period, the “Non Change in Control COBRA Payment Period”). Notwithstanding the foregoing, if the
Company determines, in its sole discretion, that the Company cannot provide the COBRA premium benefits without potentially incurring financial costs or penalties under applicable law (including, without limitation, Section 2716 of the Public
Health Service Act), the Company shall in lieu thereof pay Executive a taxable cash amount, which payment shall be made regardless of whether the Executive or his qualifying family members elect COBRA continuation coverage (the “Health
Care Benefit Payment”). The Health Care Benefit Payment shall be paid in monthly or bi-weekly installments on the same schedule that the COBRA premiums would otherwise have been paid to the
insurer. The Health Care Benefit Payment shall be equal to the amount that the Company otherwise would have paid for COBRA insurance premiums (which amount shall be calculated based on the premium for the first month of coverage), and shall be paid
until the expiration of the Non Change in Control COBRA Payment Period. 
 (ii)    In
Connection With a Change in Control. If the Company (or its successor) terminates the Executive’s employment without Cause or the Executive terminates his employment for Good Reason within the period commencing three (3) months
immediately prior to a Change in Control of the Company and ending eighteen (18) months immediately following a Change in Control of the Company (as defined in Section 4.5.4 of this Agreement), the Executive shall receive the Accrued
Amounts subject to standard deductions and withholdings, to be paid as a lump sum no later than thirty (30) days after the date of termination. In addition, subject to the limitations stated in this Agreement and upon the Executive’s
furnishing to the Company (or its successor) an executed Release within the applicable time period set forth therein, but in no event later than forty-five days following termination of employment and permitting such

  
 2. 

 
Release to become effective in accordance with its terms, and subject to Executive entering into no later than the Release Effective Date a non-competition
agreement to be effective during the Severance Period, substantially similar to Section 2.3, and continuing to abide by its terms during the Severance Period, then in lieu of (and not additional to) the benefits provided pursuant to
Section 4.4.3(i) above, the Executive shall be entitled to: 
 (a)     the equivalent of the
Executive’s Base Salary in effect at the time of termination will continue to be paid for a period of eighteen (18) months following the date of termination (hereinafter referred to as the “Change in Control Severance
Period”), less standard deductions and withholdings, to be paid during the Change in Control Severance Period according to the Company’s regular payroll practices, subject to any delay in payment required by Section 4.6 in
connection with the Release Effective Date; 
 (b)     one and half (1.5) times Executive’s
target Bonus in effect at the time of termination, or if none, one and half (1.5) times the last target Bonus in effect for Executive, less standard deductions and withholdings, to be paid in a lump sum within ten (10) days following the later
of (i) the Release Effective Date, or (ii) the effective date of the Change in Control; and 
 (c)
    in the event the Executive timely elects continued coverage under COBRA, the Company will continue to pay the same portion of Executive’s COBRA health insurance premium as the percentage of health insurance premiums
that it paid during the Executive’s employment, including any amounts that Company paid for benefits to the qualifying family members of the Executive, following the date of termination until the expiration of the Change in Control Severance
Period. Notwithstanding the foregoing, if the Company determines, in its sole discretion, that the Company cannot provide the COBRA premium benefits without potentially incurring financial costs or penalties under applicable law (including, without
limitation, Section 2716 of the Public Health Service Act), the Company shall in lieu thereof pay Executive the Health Care Benefit Payment, which payment shall be made regardless of whether the Executive or his qualifying family members elect
COBRA continuation coverage. The Health Care Benefit Payment shall be paid in monthly or bi-weekly installments on the same schedule that the COBRA premiums would otherwise have been paid to the insurer. The
Health Care Benefit Payment shall be equal to the amount that the Company otherwise would have paid for COBRA insurance premiums (which amount shall be calculated based on the premium for the first month of coverage), and shall be paid until the
expiration of the Change in Control Severance Period. 
 (iii)    No Duplication of
Benefits. For the avoidance of doubt, in no event will Executive be entitled to benefits under Section 4.4.3(i) and Section 4.4.3(ii). If Executive commences to receive benefits under Section 4.4.3(i) due to a qualifying
termination prior to a Change in Control and thereafter becomes entitled to benefits under Section 4.4.3(ii), any benefits previously provided to Executive under Section 4.4.3(i) shall offset the benefits to be provided to Executive under
Section 4.4.3(ii) and shall be deemed to have been provided to Executive pursuant to Section 4.4.3(ii).” 

  
 3. 

 2.    Section 4.4.4 of the Employment Agreement.
Section 4.4.4 of the Employment Agreement is hereby amended and restated in its entirety to read as follows: 

“4.4.4    Equity Award Acceleration. 

(i)    Not in Connection With a Change in Control. In the event that the Executive’s
employment is terminated without Cause or for Good Reason and Section 4.4.4 (ii) below does not apply, the vesting of any equity awards granted to Executive that vest solely subject to Executive’s continued services to the Company (the
“Time-Based Vesting Equity Awards”) shall be deemed vested and immediately exercisable (if applicable) by the Executive with respect to such number of shares as determined in accordance with their applicable vesting schedules
as if Executive had provided an additional twelve (12) months of services as of the date of termination. Treatment of any performance based vesting equity awards will be governed solely by the terms of the agreements under which such awards
were granted and will not be eligible to accelerate vesting pursuant to the foregoing provision. 

(ii)    In Connection With a Change in Control. In the event that the Executive’s
employment is terminated without Cause or for Good Reason within the three (3) months immediately preceding or during the eighteen (18) months immediately following a Change in Control of the Company (as defined in Section 4.5.4 of
this Agreement), the vesting of any Time-Based Vesting Equity Awards granted to Executive shall be fully accelerated such that on the effective date of such termination (or if later, the date of the Change in Control) one hundred percent (100%) of
any Time-Based Vesting Equity Awards granted to Executive prior to such termination shall be fully vested and immediately exercisable, if applicable, by the Executive. Treatment of any performance based vesting equity awards will be governed solely
by the terms of the agreements under which such awards were granted and will not be eligible to accelerate vesting pursuant to the foregoing provision. 

(iii)    Release and Waiver. Any equity vesting acceleration pursuant to this
Section 4.4.4 shall be conditioned upon and subject to the Executive’s delivery to the Company of a fully effective Release in accordance with the terms specified by Section 4.4.3 hereof and such vesting acceleration benefit shall be
in addition to the benefits provided by Section 4.4.3 hereof.” 
 3.    Effect of Amendment.
Except as expressly modified by this Amendment, the Employment Agreement shall remain unmodified and in full force and effect. 

4.    Governing Law. This Amendment shall be governed by the laws of the State of Illinois, without regard
to any conflicts of law principals thereof that would call for the application of the laws of any other jurisdiction. 

5.    Counterparts. This Amendment may be executed via facsimile or electronic (i.e., PDF) transmission and
in any number of counterparts, each of which shall be deemed an original, but all of which together shall constitute one instrument. 

[Remainder of Page Intentionally Left Blank] 

  
 4. 

 IN WITNESS WHEREOF, the
parties have executed this First Amendment to Executive Employment Agreement as of the date first written above. 
  

			
	COMPANY:
	
	HORIZON PHARMA, INC.
	HORIZON PHARMA USA, INC.
		
	By:	 	 /s/ Timothy P. Walbert

	TIMOTHY P. WALBERT, CHAIRMAN, PRESIDENT AND CHIEF EXECUTIVE OFFICER
	
	EXECUTIVE:
	
	 /s/ Michael DesJardin

	MICHAEL DESJARDINEX-10.70

 Exhibit 10.70 

CONSULTING AGREEMENT 

THIS CONSULTING AGREEMENT is made by and between Horizon Pharma USA, Inc.
with its principal place of business at 150 South Saunders Road, Lake Forest, Illinois 60045 (“Company”), and DAVID HAPPEL, an individual residing at PO Box 203, 2362 Caballo
Ranchero Drive, Diablo, CA 94528 (“Consultant”), effective February 1, 2018 (the “Effective Date”), for the purpose of setting forth the exclusive terms and conditions by which Company will acquire
Consultant’s services on a limited and temporary basis. Company and Consultant may be referred to herein individually as a “Party,” or collectively as the “Parties.” 

In consideration of the mutual obligations specified in this Agreement, and any compensation paid to Consultant for his or her services, the
Parties agree to the following: 
 1.    Work, Payment and Term. Attached to this Agreement as
EXHIBIT A hereto is a statement of the work performed or to be performed by Consultant, the payment terms for such work, the types of any expenses to be paid in connection with such work, any Background Technology (as defined
in Section 3) to be used by Consultant in performing the work, and such other terms and conditions as the Parties deem appropriate or necessary for the performance of the work. Consultant shall perform all such work himself or herself, engaging
the assistance of other individuals only with the prior written consent of Company. 
 2.    Nondisclosure and
Trade Secrets. 
 (a)    During the term of this Agreement and in the course of Consultant’s performance
hereunder, Consultant may receive and otherwise be exposed to confidential and proprietary information owned by Company or its parent, subsidiaries or group affiliates (collectively, with Company, the “Company Group”) or received by
Company Group from third parties pursuant to an obligation of confidentiality with respect thereto, relating to the Company Group’s business practices, strategies and technologies. Such confidential and proprietary information may include, but
not be limited to, any compound, chemical, peptide, protein, complex, conjugate, virus, extract, media, vector, cell, cell component, cell line, formulation or sample; any procedure, discovery, invention, formula, data, result, idea or technique;
any trade secret, trade dress, copyright, patent or other intellectual property right, or any registration or application therefor, or materials relating thereto; and any information relating to any of the foregoing or to any research, development,
manufacturing, engineering, marketing, servicing, sales, financing, legal or other business activities or to any present or future products, prices, plans, forecasts, suppliers, clients, customers, employees, consultants or investors; whether in
oral, written, graphic or electronic form (collectively referred to as “Information”). 

(b)    Consultant acknowledges the confidential and secret nature of the Information, and agrees that the
Information is the extremely valuable property of the Company Group or of the third party from which the Company Group received such Information. Accordingly, Consultant agrees not to reproduce any of the Information in any format, not to use the
Information except in the performance of the work described in this Agreement, and not to disclose all or any part of the Information in any form to any third party, such obligations shall apply in each case during the term of this Agreement and for
a period of ten (10) years thereafter, except with the prior written consent of Company. Upon termination of this Agreement for any reason, including expiration of the term of this Agreement, Consultant agrees to cease using and to return to
Company all whole and partial copies and derivatives of the Information, whether in Consultant’s possession or under Consultant’s direct or indirect control. 

  
 Page 1 

 (c)    Consultant shall not disclose or otherwise make available to
Company in any manner any confidential information of Consultant or any information received by Consultant from third parties, unless Company first agrees in writing to receive such information. 

3.    Ownership of Work Product. 

(a)    Consultant shall specifically describe and identify in EXHIBIT A to this Agreement any and all technology,
including without limitation information, materials and related intellectual property rights, which (i) Consultant intends to use in performing the work under this Agreement, (ii) is either owned solely by Consultant or controlled by
Consultant such that Consultant possesses the right to grant a license or sublicense thereunder and (iii) is in existence prior to the Effective Date (“Background Technology”). 

(b)    Consultant agrees that any and all ideas, developments, discoveries, improvements, inventions and works of
authorship conceived, written, created, tested, or first reduced to practice in the performance of work under this Agreement, including but not limited to any and all ideas, developments, discoveries, improvements, inventions and works of authorship
that are in any way conceived, written, created, improved, tested or first reduced to practice by use of any of the Company Group’s supplies, equipment, facilities, resources, or trade secret information, together with all intellectual property
rights relating thereto (“Work Product”) shall be the sole and exclusive property of Company. Consultant hereby assigns and transfers to Company all its right, title and interest in and to any and all such Work Product. If
Consultant has any rights to Work Product that cannot, under applicable law, be assigned to Company, Consultant unconditionally and irrevocably waives the enforcement of such rights and all claims and causes of action of any kind against Company
with respect to such rights. Consultant agrees, at the Company’s request and expense, to consent to and join in any action to enforce such rights. If Consultant has any right to Work Product that can neither be assigned to Company nor waived by
Consultant, Consultant hereby grants to Company an exclusive, irrevocable, perpetual, worldwide, fully paid and royalty free license, with rights to sublicense through multiple levels of sublicensees, to develop, make, have made, use, sell, have
sold, offer for sale and import such Work Product. Consultant agrees to maintain written records of all Work Product and to promptly make full written disclosure to Company of all Work Product. 

(c)    Company acknowledges that Consultant shall retain all of Consultant’s rights in any Background
Technology. Consultant hereby grants to Company a non-exclusive, irrevocable, perpetual, worldwide, fully paid and royalty free license, with rights to sublicense through multiple levels of sublicensees, under
the Background Technology to develop, make, have made, use, sell, have sold, offer for sale and import Company products, including Work Product. 

(d)    Consultant further agrees to execute all papers, including without limitation all patent applications,
invention assignments and copyright assignments, and otherwise assist Company as reasonably required to perfect Company’s right, title and interest in Work Product as expressly granted to Company under this Agreement. Such assistance shall
include but not be limited to providing affidavits or testimony in connection with patent interference, validity or infringement proceedings and participating in other legal proceedings. Reasonable costs related to such assistance, if required,
shall be paid by Company. Consultant’s obligation to assist Company as described above in this paragraph shall continue beyond the termination of this Agreement. If Company is unable, after reasonable effort, to secure Consultant’s
signature on any document as provided in this Section 3, Consultant hereby designates and appoints Company and its duly authorized officers and agents as its agent and 

  
 Page 2 

 
attorney in fact to execute, verify and file applications, and to do all other lawfully permitted acts necessary to achieve the intent of this Section 3 with the same legal force and effect
as if executed by Consultant. 
 4.    Conflicting Engagements. Consultant will notify Company in writing
prior to entering into any employment or consulting arrangement with one or more third parties which involves either subject matter substantially similar to services that Consultant is to provide hereunder, services which Consultant is to provide
for the benefit of third parties who are competitors of Company or services that Company might reasonably determine would impair Consultant’s ability to provide the services described in Exhibit A or otherwise fulfill his responsibilities or
obligations provided for in this Agreement. During the term of this Agreement, Consultant shall not accept any employment or consulting work which conflicts with Consultant’s obligations to Company hereunder or which may involve use or
disclosure of Information other than as permitted hereunder. Company expressly acknowledges that Consultant’s employment with Chrono Therapeutics (www.chronothera.com) is not a conflicting engagement under this Section 4. 

5.    Term; Termination. The term of this Agreement shall be for a period beginning on February 1, 2018
and ending on January 31, 2019 (the “Term”), unless previously terminated pursuant to this Section 5. During the Term, Company may terminate this Agreement upon ten (10) days prior written notice to Consultant, with
no further obligations or liability owed to Consultant, if Company reasonably determines that Consultant: (1) materially breaches this Agreement in any manner, including, inter alia, a breach of Section 4, or (2) commits any acts, or
engages in any activities, that Company reasonably determines are unlawful, dishonest or detrimental to the best interests of Company. 
 In
the event this Agreement is terminated or expires, for whatever reason, Consultant shall cease work immediately after receiving notice from Company, return all Information (including all copies thereof) as provided in Section 2, deliver all
Work Product and related documentation to Company, and provide Company with an invoice for any work for which compensation has not already been paid. If compensation has been advanced to Consultant, Consultant shall reimburse any amounts for which
work has not been performed prior to the date of the notice of termination. Sections 2, 3, 5, 6, 7, 10, 11, 12, 13, 14, 15, 16 and 17 shall survive the termination of this Agreement for any reason, including expiration of the term of this Agreement.

 6.    Compliance with Applicable Laws. Consultant warrants that all materials supplied and work
performed under this Agreement shall be in compliance with all applicable laws and regulations. 

7.    Independent Contractor. Consultant is an independent contractor, is not an agent or employee of
Company and is not authorized to act on behalf of Company. Consultant will not be eligible for any employee benefits, nor will Company make deductions from any amounts payable to Consultant for taxes or social securities. Payment of all taxes and
social securities due on any amounts paid to Consultant hereunder shall be the sole responsibility of Consultant. 

8.    Non-Solicitation. For the period of this Agreement and for one
(1) year thereafter, Consultant will not, either directly or indirectly, solicit or attempt to solicit any employee, independent contractor, or consultant of Company to terminate his, her, or its relationship with, Company in order to become an
employee, consultant, or independent contractor to or for any other person or entity. 

  
 Page 3 

 9.    Assignment. The Parties’ rights and obligations
under this Agreement will bind and inure to the benefit of their respective successors and assigns, except that Consultant may not delegate or assign any of his or her obligations or rights under this Agreement without Company’s prior written
consent. 
 10.    Complete Agreement. This Agreement and EXHIBIT A attached hereto
and hereby incorporated herein, constitute the Parties’ final, exclusive and complete understanding and agreement with respect to the subject matter hereof, and supersede all prior and contemporaneous understandings and agreements relating to
its subject matter. 
 11.    Waiver; Amendment; Severability. This Agreement may not be waived, modified
or amended unless mutually agreed upon in writing by both Parties. In the event any provision of this Agreement is found to be legally unenforceable, such unenforceability shall not prevent enforcement of any other provision of the Agreement. 

12.    Choice of Law. This Agreement shall be governed by the laws of the State of Illinois, without regard
to any conflicts of law principals thereof that would call for the application of the laws of any other jurisdiction. The Parties consent to the exclusive jurisdiction and venue of the federal court in the Northern District of Illinois, and state
courts located in the state of Illinois, county of Lake. 
 13.    Notice. For the purposes of this
Agreement, notices, demands, and all other forms of communication provided for in this Agreement shall be in writing and shall be deemed to have been duly given when delivered or (unless otherwise specified) mailed by registered mail, return receipt
requested, postage prepaid, or by confirmed facsimile, addressed as set forth below, or to such other address as any party may have furnished to the other in writing in accordance herewith, except that notices of address shall be effective only upon
receipt, as follows: 
 If to Company: 

Horizon Pharma USA, Inc. 
 150
South Saunders Road 
 Lake Forest, IL 60045 

Attention: Human Resources, Irina Konstantinovsky 

Executive Vice President, Chief Human Resources Officer 

ikonstantinovsky@horizonpharma.com 

Fax: 224-383-3001 

A copy to: 
 Horizon Pharma
USA, Inc. 
 150 South Saunders Road 

Lake Forest, IL 60045 
 Attention:
Legal Department, Nelson Alexander 
 nalexander@horizonpharma.com 

Fax: 224-383-3001 

  
 Page 4 

 Horizon Pharma plc 

150 South Saunders Road 
 Lake
Forest, IL 60045 
 Attention: Chairman, President and CEO, Timothy P Walbert 

twalbert@horizonpharma.com 
 Fax:
847.572.1372 
 If to the Consultant: 

David Happel 
 PO Box 203 

2362 Caballo Ranchero Drive 

Diablo, CA 94528 
 Any such written notice shall
be deemed given on the earlier of the date on which such notice is personally delivered, sent by telefax with a confirmatory copy sent by first class mail, upon confirmation of receipt in case of registered mail, or electronic mail. Either party may
change its address for notices by giving written notice to the other party in the manner specified in this section. 

14.    Execution in Facsimile and Electronic Signatures. Facsimile and electronically transmitted signatures
shall have the same force and effect as original signatures. 
 15.    Execution in Counterparts. This
Agreement may be executed in one or more counterparts, each of which shall be deemed an original and all of which together shall constitute a single instrument. 

16.    Legal and Equitable Remedies. Consultant hereby acknowledges and agrees that in the event of any
breach of this Agreement by Consultant, including, without limitation, the actual or threatened disclosure of Information without the prior express written consent of Company, Company will suffer an irreparable injury, such that no remedy at law
will afford it adequate protection against, or appropriate compensation for, such injury. Accordingly, Consultant agrees that Company shall have the right to enforce this Agreement and any of its provisions by injunction, specific performance or
other equitable relief, without bond and without prejudice to any other rights and remedies that Company may have for a breach of this Agreement. 

17.    Warranty; Indemnification. Consultant warrants that he or she has good and marketable title to all
Work Product. Consultant further warrants that the Work Product shall be free and clear of all liens, claims, encumbrances or demands of third parties, including any claims by any such third parties with respect to such third parties’
intellectual property rights in the Work Product. Consultant warrants that Consultant has not been debarred under any applicable law, rule or regulation including, without limitation, Section 306 (a) or 306 (b) of the Federal Food, Drug and
Cosmetic Act (codified at 21 U.S.C. 335(a) and 335(b)). Consultant covenants that should Consultant be convicted in the future of any act for which a person can be debarred as described in any applicable law, rule or regulation including, without
limitation, Section 306 (a) or 306 (b) of the Federal Food, Drug and Cosmetic Act, Consultant shall immediately notify Company of such conviction in writing. Consultant shall indemnify, defend and hold harmless Company and its officers, agents,
directors, employees, and customers from and against any claim, liability, loss, judgment or expense (including reasonable attorneys’ and expert witnesses’ fees and costs) 

  
 Page 5 

 resulting from or arising out of any such claims by any third parties which are based upon or are the result of
any breach of such warranties. Should Company permit Consultant to use any of Company’s equipment, tools or facilities (the “Company Equipment”) in the performance of the services during the term of this Agreement, such
permission will be gratuitous and Consultant shall indemnify, defend and hold harmless Company and its officers, directors, agents and employees from and against any claim, loss, expense or judgment of injury to person or property (including death)
arising out of Consultant’s willful misconduct or negligent use of any such Company Equipment. 
 IN WITNESS WHEREFORE, the
Parties have signed this Agreement on the date first written below. 
  

			
	 TIMOTHY P. WALBERT
	  	 DAVID HAPPEL

	 HORIZON PHARMA USA, INC.
	  	
		
	 /s/ Timothy P. Walbert
	  	 /s/ David Happel

	By:	  	
		
	 Chairman, President and CEO
	  	 Consultant

	Title	  	Title:
		
	 January 23, 2018
	  	 February 19, 2018

	Date:	  	Date:

 [signature page to Consulting Agreement] 

  
 Page 6 

 EXHIBIT A 

Work to be performed: Consultant will provide services supporting the Company’s orphan drug development programs and commercialization strategies.
Consultant’s activities will be directed by Timothy P. Walbert (“Walbert”), or any Company representative designated by Walbert, and Consultant will report to Walbert, or any Company representative designated by Walbert. 

Type or rate of payment: Payment for work performed during the Term will be in an amount equal to $5,000.00 a month, payable on approximately the 15th
day of each month during the Term. 
 Travel expenses: Company will pay Consultant’s reasonable traveling expenses, incurred at Company’s
written request and with its advance approval, in accordance with the procedures that the Company establishes from time to time. 
 Other terms (if any):

  
 Page 7

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00280-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00280-of-00352.parquet"}]]